Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· April 15, 2026

CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026

View original at globenewswire.com
CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026 MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeting, the world’s largest gathering of dermat…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Even patients with active vitiligo disease (where condition is actively spreading) showed a response to afamelanotide therapy in clinical cases

    60% confidence

  • Returning to the AAD for a second year has allowed us to witness a significant maturation in the clinical dialogue surrounding vitiligo

    60% confidence

  • The overwhelming response to the Pavilion validates CLINUVEL's longstanding focus on melanocortin peptides and reinforces mission to advance clinical programs that reflect life-long needs of patients

    60% confidence

  • Clinicians are increasingly identifying practical challenges of long-term treatment dependency and prevalence of relapse upon cessation of JAK inhibitor treatment for vitiligo

    60% confidence

  • CUV105 patient data showed repigmentation following 20 weeks of afamelanotide with adjunct NB-UVB, with patients with darker skin types (Fitzpatrick IV-VI) maintaining pigmentation up to six month follow-up after therapy withdrawal

    60% confidence

  • CLINUVEL's engagement in Denver confirms a growing recognition among the medical community that the next frontier in vitiligo care must prioritise long-term physiological stability and safety beyond immune-suppression

    60% confidence

  • Afamelanotide is not currently approved for vitiligo anywhere in the world

    60% confidence

Cited in these Via News reports